Novo Up on Wegovy Pill Approval; Orsted Falls on Wind Farm Lease Suspension | Stock Movers

On this episode of Stock Movers with Lisa Mateo:

- Shares of Novo Nordisk (NVO) soared in premarket trading after the company won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly & Co. Novo will start selling the pill in the US in early January, the company said in a statement Monday. It is approved to help people lose weight or maintain previous weight loss over the long term.

- Shares of naval shipmaker Huntington Ingalls (HII) rallied ahead of the US market open after President Trump announced the Navy will build a new “Trump-class” battleship as part of the White House push to modernize a fleet that’s been hobbled by years of cost overruns and delays.

- Shares of Copenhagen-listed Orsted (ORSTED DC) declined after the company said it’s considering “all options” including legal action as it weighs how to respond to a US decision to suspend leases for five offshore wind farms, according to a statement late Monday. Orsted said its farms — Revolution Wind and Sunrise Wind — had secured all the required federal and state permits, including consulting “closely and directly” with US authorities to “to evaluate and address potential impacts to national security and defense capabilities.”

--------

Watch Bloomberg Radio LIVE on YouTube

Weekdays 7am-6pm ET

Follow us on X

Subscribe to our Podcasts:

Bloomberg Daybreak

Bloomberg Surveillance

Bloomberg Intelligence

Balance of Power

Bloomberg Businessweek

Listen on Apple CarPlay and Android Auto with the Bloomberg Business app:

Apple CarPlay

Android Auto

Visit our YouTube channels:

Bloomberg Podcasts

Bloomberg Television

Bloomberg Originals